ESPERION THERAPEUTICS INC NE's ticker is ESPR and the CUSIP is 29664W105. A total of 159 filers reported holding ESPERION THERAPEUTICS INC NE in Q1 2021. The put-call ratio across all filers is 3.39 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $30 | -98.1% | 295,200 | 0.0% | 0.00% | – |
| Q2 2023 | $1,567 | +4135.1% | 295,200 | -7.3% | 0.00% | -100.0% |
| Q1 2023 | $37 | +48.0% | 318,500 | +1066.7% | 0.01% | +100.0% |
| Q4 2022 | $25 | -100.0% | 27,300 | -24.8% | 0.00% | -70.0% |
| Q4 2021 | $384,000 | +36.7% | 36,300 | +14.9% | 0.01% | +11.1% |
| Q3 2021 | $281,000 | +71.3% | 31,600 | +89.2% | 0.01% | +80.0% |
| Q2 2021 | $164,000 | +51.9% | 16,700 | +10.6% | 0.01% | -16.7% |
| Q1 2021 | $108,000 | +163.4% | 15,100 | -34.9% | 0.01% | +50.0% |
| Q1 2019 | $41,000 | +412.5% | 23,200 | -87.1% | 0.00% | +300.0% |
| Q4 2018 | $8,000 | -97.8% | 180,500 | -14.4% | 0.00% | -95.7% |
| Q3 2018 | $366,000 | -63.6% | 210,800 | +5.7% | 0.02% | -54.0% |
| Q2 2018 | $1,005,000 | +415.4% | 199,397 | +14.5% | 0.05% | +400.0% |
| Q1 2018 | $195,000 | +323.9% | 174,100 | +187.8% | 0.01% | +233.3% |
| Q1 2017 | $46,000 | – | 60,500 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Meditor Group Ltd | 2,679,835 | $99,609,000 | 22.32% |
| Bellevue Group AG | 5,465,715 | $203,160,000 | 2.81% |
| Rhenman & Partners Asset Management AB | 455,000 | $16,912,000 | 1.50% |
| Endurant Capital Management LP | 135,901 | $5,051,000 | 1.49% |
| Boxer Capital, LLC | 975,000 | $36,241,000 | 1.25% |
| DCF Advisers, LLC | 56,500 | $2,100,000 | 1.07% |
| Pentwater Capital Management LP | 2,169,022 | $80,623,000 | 1.04% |
| Nicholas Investment Partners, LP | 235,855 | $8,767,000 | 0.95% |
| Amia Capital LLP | 20,464 | $761,000 | 0.88% |
| HAMILTON LANE ADVISORS LLC | 46,181 | $1,717,000 | 0.83% |